AMG Funds LLC lowered its holdings in shares of Quest Diagnostics Inc (NYSE:DGX) by 19.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,403 shares of the medical research company’s stock after selling 2,284 shares during the quarter. AMG Funds LLC’s holdings in Quest Diagnostics were worth $1,015,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in DGX. Amalgamated Bank grew its stake in Quest Diagnostics by 2.7% in the 2nd quarter. Amalgamated Bank now owns 17,467 shares of the medical research company’s stock valued at $1,920,000 after buying an additional 462 shares during the last quarter. Dupont Capital Management Corp grew its stake in Quest Diagnostics by 64.4% in the 2nd quarter. Dupont Capital Management Corp now owns 1,202 shares of the medical research company’s stock valued at $132,000 after buying an additional 471 shares during the last quarter. Nisa Investment Advisors LLC grew its stake in Quest Diagnostics by 1.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 37,587 shares of the medical research company’s stock valued at $4,132,000 after buying an additional 500 shares during the last quarter. Cambridge Investment Research Advisors Inc. grew its stake in Quest Diagnostics by 1.7% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 37,739 shares of the medical research company’s stock valued at $4,072,000 after buying an additional 623 shares during the last quarter. Finally, Acropolis Investment Management LLC grew its stake in Quest Diagnostics by 19.2% in the 3rd quarter. Acropolis Investment Management LLC now owns 4,225 shares of the medical research company’s stock valued at $456,000 after buying an additional 680 shares during the last quarter. Institutional investors and hedge funds own 86.00% of the company’s stock.

NYSE DGX opened at $93.21 on Thursday. The company has a current ratio of 1.15, a quick ratio of 1.09 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $12.83 billion, a price-to-earnings ratio of 17.26, a P/E/G ratio of 1.70 and a beta of 0.90. Quest Diagnostics Inc has a 52-week low of $90.54 and a 52-week high of $116.49.

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings results on Tuesday, October 23rd. The medical research company reported $1.68 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.68. The company had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.95 billion. Quest Diagnostics had a net margin of 11.30% and a return on equity of 15.71%. The business’s quarterly revenue was up 1.8% on a year-over-year basis. During the same period last year, the business posted $1.38 EPS. Research analysts forecast that Quest Diagnostics Inc will post 6.56 EPS for the current fiscal year.

A number of research firms recently issued reports on DGX. Argus set a $120.00 target price on shares of Quest Diagnostics and gave the company a “buy” rating in a research note on Friday, September 14th. Credit Suisse Group raised their target price on shares of Quest Diagnostics from $121.00 to $128.00 and gave the company an “outperform” rating in a research note on Monday, September 24th. Bank of America assumed coverage on shares of Quest Diagnostics in a research note on Friday, October 19th. They issued a “buy” rating on the stock. Mizuho set a $108.00 price target on shares of Quest Diagnostics and gave the stock a “buy” rating in a research report on Tuesday. Finally, Canaccord Genuity decreased their price target on shares of Quest Diagnostics from $118.00 to $105.00 and set a “buy” rating on the stock in a research report on Wednesday, October 24th. Eight investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $110.80.

COPYRIGHT VIOLATION NOTICE: “AMG Funds LLC Sells 2,284 Shares of Quest Diagnostics Inc (DGX)” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.dailypolitical.com/2018/11/22/amg-funds-llc-sells-2284-shares-of-quest-diagnostics-inc-dgx.html.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services.

Featured Story: What is the 52-week high/low?

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Inc (NYSE:DGX).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.